Takeda Pharmaceutical Co logo
TAKTakeda Pharmaceutical Co
Trade TAK now
Takeda Pharmaceutical Co primary media

About Takeda Pharmaceutical Co

Takeda Pharmaceutical (TSE:4502), (NYSE:TAK) is a global biopharmaceutical company focused on bringing forward innovative medicines and treatments to patients worldwide. Its operations span across several therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. Takeda is continually working on research and development projects, aiming to deliver life-transforming treatments and tackle unmet medical needs. The company's objective is not only to drive scientific discovery but also to ensure access to its medicines for people who need them the most, demonstrating a commitment to better health and a brighter future for millions around the globe.

What is TAK known for?

Snapshot

Public US
Ownership
1781
Year founded
36680
Employees
Tokyo, Japan
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Japan

Produtos e/ou serviços de Takeda Pharmaceutical Co

  • Entyvio, a monoclonal antibody for the treatment of certain chronic inflammatory bowel diseases.
  • Vyvanse, is an is FDA-approved to treat attention deficit hyperactivity disorder (ADHD) in adults and in children who are at least 6 years old.
  • Velcade, a proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma.
  • Dexilant, a proton pump inhibitor for healing and maintenance of erosive esophagitis.
  • Alunbrig, a tyrosine kinase inhibitor for treating ALK-positive metastatic non-small cell lung cancer.
  • Adynovate, a modified human coagulation factor VIII for use in Hemophilia A patients.

equipe executiva do Takeda Pharmaceutical Co

  • Mr. Christophe WeberPresident, CEO & Representative Director
  • Mr. Milano FurutaCFO & Director
  • Dr. Andrew S. Plump M.D., Ph.D.President of Research & Development and Representative Director
  • Dr. Seigo IzumoChair of Management Board
  • Mr. Haruhiko HirateMember of Management Board
  • Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa TakedaChief Accounting Officer & Corporate Controller
  • Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling Department
  • Mr. Gabriele RicciChief Data & Technology Officer
  • Mr. Christopher David O'ReillyGlobal Head of Investor Relations & Global Finance

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.